tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Natera price target raised to $268 from $255 at RBC Capital

RBC Capital analyst Conor McNamara raised the firm’s price target on Natera (NTRA) to $268 from $255 and keeps an Outperform rating on the shares as part of a broader research note on the Life Sciences Tools and Diagnostics sector. The firm is updating its model with “more realistic” multiples, the analyst tells investors in a research note. RBC added however that Natera is the market leader in liquid biopsy testing, with #1 positions in a $30B TAM that includes noninvasive prenatal testing and minimal residual disease, with potential future launches into the market-doubling opportunity of cancer screening. Additional test approvals in current markets, and a potential near-term launch in Natera’s biggest market opportunity, all give the company multiple avenues to continue to grow revenues in double digits for the sustainable future, RBC stated.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1